



### Chemetics® - Powerful platform generating innovative small molecules for tablet based medicines


Nuevolution was founded in 2001. During 2001-15, the company was financed by leading Nordic venture capital firms (SEB Ventures, Sunstone Capital and Industrifonden). Nuevolution is listed on Nasdaq Stockholm (ticker:NUE).

During 2002-2007, Nuevolution established a revolutionary novel and proprietary technology Chemetics® for the discovery of drug candidates. Chemetics® allows Nuevolution to solve disease targets, where other techniques fail, and it allows Nuevolution to identify better drug candidates faster than possible with conventional methods used by big pharma.

Since 2008, Nuevolution has made more than one agreement per year on average with biotech, big pharma, and research organizations. A core part of the company's strategy is to secure a continuous revenue stream and until today, the company has entered 17 deals including with Almirall, Amgen, Janssen, Novartis (3 deals), Merck (2 deals), Boehringer-Ingelheim and GSK realizing more than SEK 540 million in revenues and potentially up to more than SEK 8 Bn in milestones plus royalties on sales.

In 2013, Nuevolution initiated its own pipeline research and has developed a diversified pipeline (15+ programs) aiming for treatment of inflammatory diseases and cancer. One partnered and two internal programs are currently in late preclinical development. Nuevolution's owned programs have the potential to reach first study in humans in 2019, subject to financing and/or potential partnering.

### Rapid discovery of novel small molecule drug candidates



#### Chemetics®

- Perfected for small molecules (tablet based medicines)
- Perfected for synthetic biologics
- Higher success rate and lower risk
- Cost effective drug discovery

#### Pharma's state-of-the-art HTS

- SLOW
- COSTLY
- LOW success rate

#### Nuevolution drug discovery

- FAST
- CHEAP
- HIGHER success rate

### Corporate highlights

- Proprietary platform: unique, powerful and broadly validated state-of-the-art small molecule (safe, lower cost and more convenient tablet-based solutions) with more than 300 granted and pending technology and product patents
- Diversified pipeline (inflammatory diseases and cancer): 15+ wholly-owned and partnered programs; one partnered and two internal programs in late preclinical development; potential first human study in 2019
- Partners: 17 drug discovery and development partnerships with top tier pharma companies incl. Almirall, Amgen, Janssen, Novartis, Merck & Co., Boehringer-Ingelheim, GSK and more
- Cash position: SEK 111.1 million (31 December 2018)
- Corporate: founded in 2001; listed on Nasdaq Stockholm; 47 employees in Copenhagen, Denmark

**Team**
**Board of Directors:**

Stig Løkke Pedersen, Chairman  
Søren Lemonius  
Lars Henriksson  
Jutta Heim  
Jeanette Woods

**Executive Management:**


Alex Haahr Gouliaev, CEO  
Thomas Franch, CSO  
Ton Berkien, CBO  
Johnny Stilou, CFO

**Investment case**

- Unique and validated state-of-the-art platform generating innovative drug candidates in a wide range of therapeutic areas
- Well funded business supporting the on-going discovery in 15+ programmes, both wholly-owned and in partnership, offering a balanced risk/reward profile
- Company has the potential to enter clinical studies in 2019. The Company's partnered ROR $\gamma$ t inhibitor program for treatment of psoriasis, psoriatic arthritis alone, addresses a market larger than \$ 8 Bn (2017)
- Multiple partnerships with pharmaceutical companies having the potential to collectively generate SEK 8 Bn in non-dilutive cash through milestone payments plus attractive royalties on net sales
- Not a one trick pony: Expanding pipeline with numerous discovery and pre-clinical catalysts from proprietary and partnered programs. Ambition to build broad portfolio of multiple valuable programs in clinical development

**Diversified shareholder base**

- **Market:** Nasdaq Stockholm
- **Ticker:** NUE
- **Number of shares:** 49,524,903
- **Market value (31.12.2018):** SEK 842 million
- **Share price range (6M):** 14.06-17.14 SEK/share
- **Share price (31.12.2018):** 17.00 SEK/share


**Hybrid business model: 20+ programmes from discovery to preclinical, 4 outlicensed programs, 4 partners**

Program	Indication	Discovery	Preclinical	Phase I	Partner
ROR $\gamma$ t inhibitor	Psoriasis, PsA AS, IBD	██████████	██████████	██████████	Almirall NUEVOLUTION
BET-BD1	Fibrosis, AD, Oncology	██████████	██████████		NUEVOLUTION
IL-17A	Inflammation	██████████	██████████		NUEVOLUTION
RIPK1 inhibitor	Inflammation, Oncology	██████████	██████████		NUEVOLUTION
TYK2 inhibitor	Inflammation	██████████	██████████		NUEVOLUTION
ROR $\gamma$ t agonist	Immunooncology	██████████	██████████		NUEVOLUTION
GRP78	Oncology	██████████	██████████		NUEVOLUTION CANCER RESEARCH ICR
10+ research programs	Oncology, Inflammation	██████████			NUEVOLUTION
<b>Collaborations</b>					
Multi-target	Oncology, CNS	██████████	██████████		AMGEN
Multi-target	Oncology, Inflammation, Infectious diseases	██████████	██████████		janssen
NSD1, 2, 3	Hematological cancers	██████████			BRAC

**Contact**

Nuevolution AB (publ)  
Rønnegade 8, 2100 Copenhagen, Denmark  
Phone: +45 7020 0987  
Email: [info@nuevolution.com](mailto:info@nuevolution.com)

**Investor relations**  
Johnny Stilou, CFO  
Phone: +45 8877 5973  
Email: [jost@nuevolution.com](mailto:jost@nuevolution.com)